Introduction
of the kiwifruit allergic patients were sensitized to at least one of these allergens from kiwi 90 seeds, suggesting that their inclusion in CRD of kiwifruit allergy might well contribute to 91 improve the diagnostic sensitivity. Prior to the inclusion of these molecules in CRD 92 approaches, a comprehensive characterization of both purified allergens is mandatory. 93
The aim of this study was to characterize from structural and immunological point 94 of view the purified Act d 12 and Act d 13 from kiwi seeds and to investigate the potential 95 implication of these allergens in IgE cross-reactivity involving kiwi, peanut and tree nuts. 96
Results

110
Act d 12 and Act d 13 display common structural features to their homologous 111 counterparts from the 11S globulin and 2S albumin protein families 112
Act d 12 (11S globulin) and Act d 13 (2S albumin) of around 51 and 12 kDa, respectively, 113 are two novel allergens contained kiwi seeds extract that display IgE-reactivity in 114
immunoblotting with a pool of sera from kiwifruit allergic patients (Fig. 1A) . We purified 115 both allergens to homogeneity following the sequential chromatographic steps described in 116 the online repository ( Supplementary Fig. 1 ). The purity and structural integrity of the 117 as demonstrated by negative staining with the lectin Concanavalin A (Fig. 1D) . The CD 125 spectra in the far-UV of purified Act d 12 and Act d 13 showed that both allergens display a 126 Act d 12 (53%) (Fig. 3C ). When Act d 13 was used as inhibitor, a 34% of inhibition was 162 reached, and when the pool of sera was pre-incubated with the mixture of both allergens, 163 the inhibition was around 80% (Fig. 3C) . 164
The allergenic capacity of Act d 12 and Act d 13 was assessed by in vitro BAT. 165 Both purified allergens demonstrated capacity to induce IgE cross-linking in effector 166 circulating basophils (Fig. 3D) . Kiwifruit allergic patients with specific IgE to kiwi seeds 167 extract and to Act d 12 or Act d 13 showed positive BAT with kiwi seeds extract, purified 168 Act d 12 or Act d 13 with median SI values of x± y, z ± w and m ± n, respectively (Fig 3D) . 169
170
Act d 12 and Act d 13 from kiwi seeds show in vitro IgE cross-reactivity with homologous 171
counterparts from peanut and tree nuts 172
We performed in vitro IgE-inhibition experiments in immunoblotting. We pooled the sera 173 from kiwifruit allergic patients sensitized to peanut and tree nuts into two groups (Table I) : 174 i) patients with specific IgE to Act d 12, and ii) patients with specific IgE to Act d 13. The 175 IgE reactivity to the protein of 51 kDa in kiwi seeds extract was totally abolished when the 176 pool of sera from patients sensitized to Act d 12 was preadsorbed to kiwi seeds extract or 177 to the purified Act d 12 (Fig. 4A) . The IgE-binding to purified Act d 12 was significantly 178 inhibited by peanut, almond, hazelnut and walnut (86%, 67%, 66% and 65%, respectively) 179 and completely inhibited by kiwi seeds extract or purified Act d 12 (Fig. 4B) . The IgE-180 reactivity to the protein of 12 kDa in kiwi seeds extract was also completely inhibited when 181 the pool of sera from patients sensitized to Act d 13 was preadsorbed to kiwi seeds extract 182 or to the purified Act d 13 (Fig. 4C) mM). In all the cases, the aliquots withdrawn at different times were frozen and stored
Results 133
First, proteins contained in lyophilized defatted kiwi seeds extract were separated by 134 size-exclusion chromatography (Supplementary Fig. 1A ). Fractions containing proteins 135 of around 51 and 12 kDa were pooled in two different batches according to CBS and 136
IgE-reactivity after SDS-PAGE ( Supplementary Fig. 1A, inset) . Act d 12 was further 137 purified to homogeneity from batch 1 by ion-exchange chromatography 138 (Supplementary Fig. 1B) . The purified Act d 12 migrated as a single protein in SDS-139 PAGE under non-reducing conditions and retained the IgE-binding capacity 140
( Supplementary Fig. 1B, inset) . Act d 13 was purified from batch 2 by RP-HPLC and 141 also migrated as a single monomer of around 12 kDa under non-reducing conditions 142 and retained the IgE-binding capacity ( Supplementary Fig. 1C, inset) .
